Angle PLC Parsortix Colorectal Cancer Validation (7804I)
July 08 2013 - 2:00AM
UK Regulatory
TIDMAGL
RNS Number : 7804I
Angle PLC
08 July 2013
For immediate release 8 July 2013
ANGLE plc
("ANGLE" or "the Company")
PARSORTIX COLORECTAL CANCER PATIENT BLOOD VALIDATION
ANGLE plc (AIM: AGL), the specialist medtech company, is pleased
to announce successful results from third party testing of its
Parsortix non-invasive cancer diagnostic product on colorectal
cancer patient blood.
The Parsortix system comprising the PR1 machine and the GEN3
cassette was tested on cancer patient blood by the University of
Surrey Oncology Group (Surrey) and has been found to be performing
well.
Surrey researchers first undertook a wide range of testing on
controlled spiked samples (cultured cancer cells added to healthy
volunteer blood) with a variety of different types of cancer. This
testing enabled them to compare capture and harvesting of cells
against known numbers of spiked cells and was completed
successfully as a pre-cursor to testing the blood of cancer
patients. Surrey also developed and refined formal cell
identification techniques with the Parsortix system.
Following a number of successful separations of the blood of
patients with a variety of different cancers, Surrey has completed
a structured analysis of colorectal cancer patient blood undertaken
by a hepatopancreobiliary surgeon from the Royal Surrey County
Hospital.
Cells from 2ml samples of whole blood from 20 colorectal cancer
patients were separated and harvested using the Parsortix system.
The harvested cells were investigated by Surrey to identify and
count the CTCs (circulating tumour cells) in the patients'
blood.
Of the 20 patients tested, 75% were found positive for CTCs.
This is an impressive result as it is more than double the level
recorded in the published literature*, which suggests that a
positive CTC count (defined as 2 or more CTCs in 7.5ml of blood)
will be found in less than half this number of patients. The
effectiveness of the Parsortix cell harvest is even more pronounced
as only 2ml of blood was used, less than one third of the sample
volume used in the published studies.
Surrey has subsequently demonstrated that, through the use of
the simple and established Ficoll gradient process as a
pre-separation enrichment step, the Parsortix system is capable of
running much larger blood volumes fast and effectively through the
system without reducing the capture and harvest capabilities of the
system.
Using this approach, a 20ml patient blood sample can now be
processed through the Parsortix system in under an hour.
Given the scale and severity of colorectal cancer, it is a major
target for the Parsortix system. More than 1.2 million people
develop colorectal cancer every year globally, and more than
600,000 people die of the disease.
Head of the University of Surrey's Oncology Group in the Faculty
of Health and Medical Sciences, Professor Hardev Pandha,
commented:
"The Parsortix system is working well. It is simple to use and
is proving highly sensitive in its ability to harvest circulating
tumour cells from patient blood. The cells are harvested without
antibody capture so there is huge potential as a liquid
biopsy."
ANGLE's Founder and Chief Executive, Andrew Newland,
commented:
"We are delighted that the University of Surrey's independent
validation of the Parsortix system has shown it to be working well
and believe that the Parsortix liquid biopsy has the potential to
make a major contribution to more effective treatment of cancer
patients.
"The University's success in using the Ficoll gradient with the
Parsortix system is important as the ability to process larger
blood volumes increases the sensitivity of the system further
differentiating Parsortix from the competition."
*Allard WJ, Matera J, Miller MC et al. Clin Cancer Res 2004; 10:
6897-6904 found 30% of colorectal cancer patients positive for CTCs
and Sastre J, Maestro ML, Puente J et al. Annals of Oncology 19:
935-938, 2008 found 36.2% colorectal cancer patients positive for
CTCs.
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Adrian Hargrave, Stephen Keys (Nominated
adviser)
Andy Roberts, Christian Hobart (Sales) 020 7397 8900
Buchanan
Mark Court, Fiona Henson, Sophie Cowles 020 7466 5000
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFMGGNKRDGFZG
Angle (LSE:AGL)
Historical Stock Chart
From May 2024 to Jun 2024
Angle (LSE:AGL)
Historical Stock Chart
From Jun 2023 to Jun 2024